Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527
Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications
ALG.APV-527 was the subject of a collaboration agreement announced by the companies in
“With CMC and IND enabling activities underway, our partnership with Aptevo is moving ahead rapidly,” said Per Norlén, Chief Executive Officer of
“The timely progress we are making underscores our respective companies’ expertise in bispecific antibody engineering and we are very excited to begin the next phase of development of ALG.APV-527 and further demonstrate the elegance of our ADAPTIR technology platform,” said
About
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo’s outlook, financial performance or financial condition, our technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, Aptevo’s future growth rates, Aptevo’s ability to timely manufacture its products, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; the ability of our contractors and suppliers to supply product and materials; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or markets and our ability to retain patients; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the
For Further Information:Aptevo Therapeutics Stacey Jurchison , Sr. Director, Investor Relations and Corporate Communications 206-859-6628 JurchisonS@apvo.comAlligator Bioscience Per Norlén, CEO E-mail: per.norlen@alligatorbioscience.com Rein Piir VP, Investor Relations +46 708 537292 rein.piir@alligatorbioscience.com